Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology.

Area of Science:

• Oncology
• Genomics
• Bioinformatics

Background:

• Genomic testing is integral to modern oncology care, aiding diagnosis, prognosis, and treatment selection.
• The proliferation of genomic testing providers and platforms complicates panel selection.
• Key considerations include the sufficiency of alteration interpretation and therapy matching services.

Purpose of the Study:

• To review common commercial sequencing platforms, detailing genes, alteration types, sample requirements, and reporting.
• To explore publicly available resources for independent alteration interpretation and identification of genomically matched treatments.
• To discuss limitations in interpretation and nomenclature, and present a tool for assessing evidence levels for treatment options.

Main Methods:

• Systematic review of commercially available genomic sequencing platforms.
• Curated review of publicly accessible bioinformatics and clinical trial matching resources.
• Development and validation of a tool for standardizing the assessment of evidence levels for targeted therapies.

Main Results:

• Commercial platforms vary in gene coverage, alteration detection, and reporting comprehensiveness.
• Publicly available resources offer valuable alternatives for interpretation and treatment matching, albeit with caveats.
• A novel tool facilitates interoperable assessment of evidence supporting treatment recommendations based on molecular profiles.

Conclusions:

• Selecting the appropriate genomic testing platform requires careful consideration of technical specifications and interpretation support.
• Utilizing a combination of commercial services and public resources can optimize genomic data interpretation and treatment selection.
• Standardized evidence assessment is crucial for prioritizing genomically informed treatment strategies in oncology.